In an 18-month follow-up study conducted by Muniesa involving 67 patients (48 with MF, 7 with SS, and 12 with CD30+ lymphoproliferative disorders [LPD]), BV achieved an overall response rate (ORR) of 67% (63% in MF, 71% in SS, and 84% in CD30+ LPD). This evidence concerns the gene TNFRSF8 and synovial sarcoma.